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Dexketoprofen trometamol (DT), a nonsteroidal anti-inﬂammatory drug, is a highly water-soluble salt
and active enantiomer of rac-ketoprofen. Its parenteral form is commonly used for acute pain man-
agement in emergency departments of our country. Side effects such as diarrhea, indigestion, nausea,
stomach pain, and vomiting may be seen after the use of DT. Anaphylactic shock (AS) secondary to
infusion of DT is very rare and, to our knowledge, it is the ﬁrst case report describing this side effect. This
case report was presented to emphasize that AS may be seen after the use of DT.
Copyright © 2016 The Emergency Medicine Association of Turkey. Production and hosting by Elsevier
B.V. on behalf of the Owner. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dexketoprofen trometamol (DT), a nonsteroidal anti-
inﬂammatory drug, is a highly water-soluble salt and active enan-
tiomer of rac-ketoprofen.1 It is licensed in a number of countries.
Oral DT was approved in the European countries through a Mutual
Recognition Procedure in 1998 and parenteral formulation in
2002.1 Parenteral DT is widely used in acute pain management in
the emergency department (ED) settings.2e4 Although diarrhea,
indigestion, nausea, stomach pain, and vomiting are described as
common adverse drug reactions in the product information of DT,
anaphylactic shock (AS) secondary to use of DT is very rare with an
incidence of <0.01%.5 Here, we present an instance of AS occurring
after intravenous (IV) infusion of DT and, to our knowledge; this is
the ﬁrst case report of this association.
2. Case presentation
A 43-year-old female patient was admitted to the ED with a
complaint of right ﬂank pain. The patient had a medical history of
urological stone disease, but had not been taking any drugs regu-
larly. The patient denied any drug allergy history. She had no his-
tory of any alcohol, substance, or tobacco use. In the physical
examination (PE), there was costovertebral angle tenderness in ther).
ncy Medicine Association of
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ons.org/licenses/by-nc-nd/4.0/).right ﬂank region. The rest of the PE revealed no pathology. She
stated that this pain was identical to the previous renal colic pain.
Bedside renal ultrasonography revealed dilatation in the right uri-
nary structures but no urinary stone. It was determined that the
patient was suffering from renal colic. The patient was taken to the
observation unit and then 50 mg of DT (Arveles® 50 mg/2 ml
Ampul, UFSA _Ilaç) was administered at a 10-min IV infusion for pain
management. During infusion, she developed ﬂushing in the face
and neck, confusion, tachypnea, tachycardia (pulse rate: 150 beats
per minute), hypotension (blood pressure: 70/30 mmHg), and
uvular edema; so she was diagnosed as having AS. Infusion was
stopped, and we administered adrenaline 0.5 mg intramuscularly
and pheniramine maleate 45.5 mg (Avil® 45.5 mg/2 ml, Sandoz)
intravenously. An additional IV line was established on the other
upper extremity, and a saline solution was given through both of
them. The patient's symptoms declined and her clinical condition
improved in the following hours. The dermatology department was
consulted. The dermatologist prescribed dual antihistaminic ther-
apy and suggested observation of the patient. The patient was
discharged after a 12-h follow-up in the observation unit. She was
given the information that she has a severe allergy to DT.3. Discussion
Hepatic injury with neutropenia, thrombocytopenia, and acute
kidney injury due to massive rhabdomyolysis have been reported
previously related to the use of DT perorally.6,7 To our knowledge,
the case presented here is the ﬁrst instance in the literature of AS
after the use of DT intravenously. Parenteral DT is widely used inn and hosting by Elsevier B.V. on behalf of the Owner. This is an open access article
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administered DT has a good tolerability proﬁle and high analgesic
potency.1,8,9 Common adverse effects of DT include diarrhea, indi-
gestion, nausea, stomach pain, and vomiting.5 Besides nonspeciﬁc
allergic reactions like dizziness, rash, skin eruptions, and vomiting,
AS may also be seen.5 Although the probability of AS after IV
infusion of DT is <0.01%, it is not clear whether the risk is smaller
when it is given through the peroral route.5 It has been reported
that dexketoprofen pharmacokinetics following IV and intramus-
cular routes allow for a potential advantageous rapid switch to the
oral formulation.10 However, there is not any controlled clinical
study showing that allergic reactions can be reduced by choosing
the oral administration instead of the IV administration. Intrave-
nous DT administration is commonly used in acute pain manage-
ment in our ED. Allergic reactions even AS may develop after the
use of DT intravenously.
The clinical symptoms of the anaphylaxis varies from urticaria,
edema of lips and uvula, dizziness, cough, and vomiting to stridor,
wheezing, respiratory distress, hypoxia, hypotension, and even
death.11 Edema of the uvula as well as dyspnea, confusion, and
hypotension were present in our patient.
The presented case is important because the patient's symp-
toms, which occurred after the use of DT intravenously, are
consistent with AS. In our case, Naranjo's adverse drug reaction
causality scale score was calculated as 6, which means that a causal
relation between the drug and an adverse reaction is “probable”.12
Possible limitations of the causal relation are not being able to
measure DT levels in any body ﬂuid sample and not having the
chance to administer the drug to monitor if the adverse reaction
occurs again (re-challenge).
After the airway, breathing, and circulation are checked and
secured, an adult patient with AS was treated with 0.3e0.5 mg
adrenaline (1:1000 solution) by intramuscular injection.11 Adren-
aline was given intramuscularly and pheniramine maleate was
given intravenously in our patient. Edema of uvula and ﬂushing in
the face and neck had subsided, and tachycardia, hypotension and
confusion were resolved during follow-up period. The patient wasdischarged from ED without any sequela.
In conclusion, DT is commonly used intravenously in acute pain
management in the ED. Although it is rarely seen, AS may develop
after IV use of the DT. Emergency medicine physicians should
remember that there is some risk of development of AS in patients
treating DT intravenously.References
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